カルナバイオサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2017/12/06 | 1,191 | 1,194 | 1,167 | 1,179 | -18 | -1.5% | 65,900 |
| 2017/12/05 | 1,187 | 1,207 | 1,179 | 1,197 | +3 | +0.3% | 36,100 |
| 2017/12/04 | 1,204 | 1,209 | 1,185 | 1,194 | -4 | -0.3% | 55,900 |
| 2017/12/01 | 1,203 | 1,204 | 1,193 | 1,198 | -12 | -1% | 46,700 |
| 2017/11/30 | 1,201 | 1,210 | 1,192 | 1,210 | +3 | +0.2% | 43,100 |
| 2017/11/29 | 1,196 | 1,215 | 1,196 | 1,207 | -3 | -0.2% | 33,600 |
| 2017/11/28 | 1,220 | 1,223 | 1,191 | 1,210 | -6 | -0.5% | 52,800 |
| 2017/11/27 | 1,238 | 1,238 | 1,216 | 1,216 | -17 | -1.4% | 34,000 |
| 2017/11/24 | 1,239 | 1,246 | 1,228 | 1,233 | -11 | -0.9% | 34,800 |
| 2017/11/22 | 1,268 | 1,269 | 1,223 | 1,244 | +3 | +0.2% | 87,600 |
| 2017/11/21 | 1,230 | 1,251 | 1,223 | 1,241 | -6 | -0.5% | 72,200 |
| 2017/11/20 | 1,173 | 1,250 | 1,173 | 1,247 | +63 | +5.3% | 99,300 |
| 2017/11/17 | 1,164 | 1,195 | 1,158 | 1,184 | +38 | +3.3% | 84,100 |
| 2017/11/16 | 1,142 | 1,159 | 1,140 | 1,146 | +2 | +0.2% | 36,200 |
| 2017/11/15 | 1,151 | 1,163 | 1,131 | 1,144 | -11 | -1% | 72,200 |
| 2017/11/14 | 1,152 | 1,164 | 1,139 | 1,155 | +3 | +0.3% | 60,400 |
| 2017/11/13 | 1,149 | 1,167 | 1,130 | 1,152 | -73 | -6% | 162,000 |
| 2017/11/10 | 1,202 | 1,233 | 1,201 | 1,225 | +7 | +0.6% | 70,600 |
| 2017/11/09 | 1,240 | 1,243 | 1,211 | 1,218 | -40 | -3.2% | 105,000 |
| 2017/11/08 | 1,251 | 1,271 | 1,242 | 1,258 | +8 | +0.6% | 39,200 |
| 2017/11/07 | 1,275 | 1,277 | 1,250 | 1,250 | -40 | -3.1% | 94,400 |
| 2017/11/06 | 1,310 | 1,312 | 1,285 | 1,290 | -29 | -2.2% | 77,300 |
| 2017/11/02 | 1,360 | 1,360 | 1,303 | 1,319 | -39 | -2.9% | 74,300 |
| 2017/11/01 | 1,325 | 1,368 | 1,315 | 1,358 | +43 | +3.3% | 112,800 |
| 2017/10/31 | 1,307 | 1,324 | 1,294 | 1,315 | +5 | +0.4% | 49,900 |
| 2017/10/30 | 1,319 | 1,320 | 1,295 | 1,310 | -3 | -0.2% | 98,100 |
| 2017/10/27 | 1,274 | 1,315 | 1,268 | 1,313 | +45 | +3.5% | 116,600 |
| 2017/10/26 | 1,251 | 1,272 | 1,246 | 1,268 | +20 | +1.6% | 38,800 |
| 2017/10/25 | 1,265 | 1,275 | 1,248 | 1,248 | -8 | -0.6% | 54,400 |
| 2017/10/24 | 1,276 | 1,285 | 1,251 | 1,256 | -16 | -1.3% | 57,800 |
| 2017/10/23 | 1,264 | 1,274 | 1,241 | 1,272 | +8 | +0.6% | 74,300 |
| 2017/10/20 | 1,280 | 1,280 | 1,255 | 1,264 | -24 | -1.9% | 45,100 |
| 2017/10/19 | 1,244 | 1,288 | 1,244 | 1,288 | +45 | +3.6% | 65,300 |
| 2017/10/18 | 1,271 | 1,299 | 1,240 | 1,243 | -48 | -3.7% | 77,300 |
| 2017/10/17 | 1,235 | 1,345 | 1,228 | 1,291 | +69 | +5.6% | 275,300 |
| 2017/10/16 | 1,228 | 1,250 | 1,218 | 1,222 | -6 | -0.5% | 61,700 |
| 2017/10/13 | 1,218 | 1,229 | 1,206 | 1,228 | +14 | +1.2% | 62,800 |
| 2017/10/12 | 1,208 | 1,227 | 1,204 | 1,214 | ±0 | ±0% | 58,400 |
| 2017/10/11 | 1,224 | 1,224 | 1,209 | 1,214 | -11 | -0.9% | 77,300 |
| 2017/10/10 | 1,227 | 1,233 | 1,213 | 1,225 | -2 | -0.2% | 70,700 |
| 2017/10/06 | 1,262 | 1,266 | 1,220 | 1,227 | -40 | -3.2% | 115,400 |
| 2017/10/05 | 1,293 | 1,301 | 1,267 | 1,267 | -26 | -2% | 63,400 |
| 2017/10/04 | 1,320 | 1,338 | 1,285 | 1,293 | -31 | -2.3% | 79,000 |
| 2017/10/03 | 1,369 | 1,370 | 1,305 | 1,324 | -81 | -5.8% | 191,900 |
| 2017/10/02 | 1,248 | 1,441 | 1,247 | 1,405 | +157 | +12.6% | 531,900 |
| 2017/09/29 | 1,250 | 1,253 | 1,226 | 1,248 | +2 | +0.2% | 54,500 |
| 2017/09/28 | 1,232 | 1,260 | 1,229 | 1,246 | +25 | +2% | 73,100 |
| 2017/09/27 | 1,195 | 1,228 | 1,185 | 1,221 | +26 | +2.2% | 60,400 |
| 2017/09/26 | 1,204 | 1,204 | 1,190 | 1,195 | -15 | -1.2% | 51,400 |
| 2017/09/25 | 1,223 | 1,234 | 1,205 | 1,210 | -13 | -1.1% | 65,100 |
1701～
1750
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| 日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ＶＩＳ | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム
